-
Absci Corp. (ABSI) PT Raised to $8 at H.C. Wainwright
-
ABSCI reports human study data on hair loss treatment ABS-201
-
Absci Corp. (ABSI) PT Raised to $9 at Jones Trading
-
Absci Corporation (ABSI) Reports In-Line Q3 EPS
-
JPMorgan Starts Absci Corp. (ABSI) at Overweight
-
Absci partners with Oracle and AMD to accelerate AI drug discovery
-
Absci Corp. (ABSI) PT Lowered to $8 at Needham
-
Absci Corporation (ABSI) Misses Q2 EPS by 3c
-
iRhythm Technologies (IRTC) announces Board changes
-
Absci (ABSI) appoints Mary Szela to board of directors
-
Morgan Stanley Assumes Absci Corp. (ABSI) at Overweight
-
Absci Corporation (ABSI) Tops Q1 EPS by 1c
-
Absci Corporation (ABSI) Files for 5.71M Share Offering by Selling Stockholders
-
KeyBanc Sees 'Continued Development of Diverse Internal Pipeline' at Absci Corp. (ABSI)
-
H.C. Wainwright Reiterates Buy Rating on Absci Corp. (ABSI)
-
Absci Corporation (ABSI) Misses Q4 EPS by 3c
-
Needham Starts Absci Corp. (ABSI) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Absci Corp. (ABSI)
-
Absci Corporation (ABSI) climbs 55% following pact with AMD (AMD)
-
Absci Corporation (ABSI) and AMD (AMD) Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
-
H.C. Wainwright Reiterates Buy Rating on Absci Corp. (ABSI)
-
Jones Trading Starts Absci Corp. (ABSI) at Buy
-
Absci Corporation (ABSI) and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
-
Guggenheim Starts Absci Corp. (ABSI) at Buy
-
TD Cowen Reiterates Buy Rating on Absci Corp. (ABSI)
-
Absci Corporation (ABSI) Misses Q2 EPS by 4c
-
Morgan Stanley Starts Absci Corp. (ABSI) at Overweight
-
TD Cowen Reiterates Buy Rating on Absci Corp. (ABSI)

